The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.
The overall health-related quality of life (HRQoL) among younger patients with colorectal cancer (CRC) is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations, according to data presented during the 2021 ASCO Gastrointestinal Cancers Symposium.
Using the Functional Assessment of Cancer Therapy (FACT-C) survey, which assesses HRQoL globally, along with a cross-sectional online survey for a CRC-specific scale that looked at emotional, physical, social, and functional well-being domains, researchers evaluated the responses of 235 patients with CRC and found an overall low score of HRQoL of 67.3 out of a possible 136 in this patient population.
The mean age of the sample was 33.76 years old and the location of the patients’ tumors were either in the colon (41.7%) or rectum (58.3%). The majority of patients (33.23%) were diagnosed with stage 2 cancer and 98% were non-metastatic, while 42% experienced relapse of their disease. One hundred and eighty-nine patients (61.4%) were 6-18 months from their diagnosis or relapse, but key demographic figures like age and ethnicity did not have a significant statistical difference between the two groups.
Patients were split into two categories of 6-18 months from their initial diagnosis or relapse, and 19-36 months from diagnosis or relapse. While researchers did not find a significant difference between the two groups in terms of emotional and physical well-being, scores were low across all domains, with social well-being the highest (15.15/28) and emotional well-being the lowest (11.44/24). Moreover, functional well-being rated close to the bottom (11.84/28), with physical well-being the second highest (15.15/28).
Higher scores for physical and emotional well-being were observed in patients who had a longer time between diagnosis compared to short-term, whereas significantly lower scores were observed in social well-being for patients who had a shorter time between their diagnosis and the survey, at 15.24/28 versus 14/28 respectively (P <0.01). This was also observed in functional well-being, which scored at 13.20 for the 6-18 month group versus 11.12 for 19-36 month group (P <0.01).
The researchers concluded that with the overall low HRQoL scores for young CRC survivors in the categories of social and functional well-being should be targeted by appropriate methods, as they were the lowest. These methods would include counseling and quality of life interventions, but further study into which of these methods would be best is needed.
Reference
Ann Miller K, Stal J, Gallagher P et al. Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Abstract 34.
Belantamab Mafodotin Triplet Improves OS, Stakes a Claim as New SOC in R/R Multiple Myeloma
December 10th 2024The combination of belantamab mafodotin and bortezomib/dexamethasone improved overall survival over daratumumab plus the same doublet in patients with relapsed/refractory multiple myeloma.
Read More
Belantamab Mafodotin Triplet Improves OS, Stakes a Claim as New SOC in R/R Multiple Myeloma
December 10th 2024The combination of belantamab mafodotin and bortezomib/dexamethasone improved overall survival over daratumumab plus the same doublet in patients with relapsed/refractory multiple myeloma.
Read More
2 Commerce Drive
Cranbury, NJ 08512